Table 4

Secondary statistical analyses

ChromosomeSNPGene of interestHLA combined (n = 5,164) any IA (n = 350)*DR3/3 (n = 1,161) any IA (n = 40)*DR4/4 and DR4/8 (n = 1,922) any IA (n = 122)*DR3/4 (n = 2,081) any IA (n = 188)*mIAA as first (n = 150)*GADA as first (n = 130)*
SNPs significant for time to any autoantibody across all HLA genotypes
 1p13.2rs2476601PTPN221.54 (1.27–1.88)1.72 (0.95–3.12)1.63 (1.19–2.24)1.44 (1.09–1.90)1.67 (1.25–2.22)1.23 (0.86–1.77)
 1q31.2rs2816316RGS11.24 (1.03–1.49)0.65 (0.34–1.25)1.36 (1.00–1.85)1.31 (1.02–1.67)1.30 (0.99–1.72)1.07 (0.78–1.47)
 4p15.2rs1051708601.21 (1.04–1.42)0.75 (0.45–1.25)1.26 (0.96–1.64)1.29 (1.05–1.60)1.36 (1.07–1.72)1.06 (0.81–1.37)
 7p12.1rs4948088COBL0.62 (0.40–0.97)1.16 (0.42–3.21)0.51 (0.23–1.14)0.58 (0.31–1.09)0.44 (0.20–0.99)1.06 (0.59–1.90)
 11p15.5rs1004446INS0.77 (0.66–0.90)0.83 (0.52–1.32)0.68 (0.51–0.89)0.81 (0.65–1.00)0.83 (0.65–1.05)0.82 (0.64–1.06)
 12q13.2rs2292239ERBB31.33 (1.14–1.55)1.29 (0.83–2.02)1.37 (1.06–1.78)1.32 (1.07–1.62)1.29 (1.03–1.63)1.30 (1.01–1.67)
 12q24.12rs3184504SH2B31.38 (1.19–1.61)1.73 (1.10–2.71)1.65 (1.27–2.13)1.17 (0.95–1.43)1.41 (1.12–1.77)1.49 (1.17–1.91)
 16p13.13rs12708716CLEC16A0.84 (0.72–0.99)0.91 (0.57–1.45)0.84 (0.64–1.11)0.82 (0.66–1.02)0.85 (0.67–1.09)0.82 (0.63–1.07)
Other SNPs not significant for time to any autoantibody across all HLA genotypes
 6q23.3rs2327832TNFAIP30.90 (0.74–1.08)1.70 (1.05–2.75)0.82 (0.59–1.13)0.81 (0.63–1.06)0.93 (0.70–1.24)0.73 (0.53–1.01)
 16q23.1rs7202877CTRB21.12 (0.89–1.40)0.43 (0.16–1.19)1.34 (0.95–1.91)1.13 (0.83–1.53)1.39 (1.02–1.90)1.01 (0.69–1.48)
 17q12rs2290400ORMDL0.93 (0.80–1.08)0.90 (0.58–1.40)1.04 (0.81–1.33)0.87 (0.71–1.06)1.12 (0.89–1.40)0.76 (0.59–0.97)
 17p13.1rs169569362 genes1.02 (0.82–1.28)1.05 (0.54–2.03)1.26 (0.89–1.79)0.86 (0.62–1.20)1.37 (1.00–1.86)0.74 (0.48–1.12)
 17q21.2rs7221109CCR71.03 (0.88–1.20)1.75 (1.12–2.74)1.03 (0.80–1.33)0.91 (0.73–1.13)0.96 (0.76–1.21)1.09 (0.85–1.40)
 18q22.2rs763361CD2261.08 (0.93–1.26)1.56 (1.00–2.42)1.02 (0.79–1.31)1.04 (0.85–1.28)0.95 (0.76–1.21)1.01 (0.79–1.29)
 20p13rs2281808SIRPG0.94 (0.80–1.10)0.91 (0.57–1.45)1.27 (0.98–1.65)0.79 (0.63–0.98)1.07 (0.84–1.36)0.99 (0.77–1.28)
  • Summary of associations to autoantibody positivity, time to any autoantibody (n = 350) across HLA categories (n = 5,164), split by HLA categories and by specific autoantibodies. The factors indicating nominal significant risk or protection are indicated in bold.

  • *HR (95% CI).